Roger A. Moorehead
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Studies from our lab demonstrated that increasing miR‐200 expression in human triple negative breast cancer (TNBC) reduced tumor growth and metastasis In Vivo. In this study, we found that overexpression of miR‐200s in TNBC cells significantly reduced the expression of JAG1 . When JAG1 was knocked out in MDA‐MB‐231 cells proliferation and invasion were significantly reduced In Vitro. Moreover, loss of JAG1 inhibited mammary tumor growth and metastasis In Vivo. RNA sequencing revealed that loss of JAG1 altered the expression of genes associated with the ECM, angiogenesis, and EMT. These results imply that miR‐200s may mediate some of their antitumor actions through reducing JAG1 expression and suggest that agents targeting JAG1 should be further evaluated as a therapeutic strategy for TNBC.
Year:
2025
Although significant progress in the treatment of breast cancer has been achieved, toxic therapies would not be required if breast cancer could be prevented from developing in the first place. While breast cancer prevention is difficult to study in humans due to long disease latency and stochastic cancer development, transgenic mouse models with 100% incidence and defined mammary tumor onset, provide excellent models for tumor prevention studies. In this study, we used Neu/Erbb2 transgenic mice (MTB‐TAN) as a model of human HER2 + breast cancer to investigate whether a family of microRNAs, known as the miR‐200 family, can prevent mammary tumor development. Overexpression of Neu induced palpable mammary tumors in 100% of the mice within 38 days of Neu overexpression. When the miR‐200b/200a/429 cluster was co‐overexpressed with Neu in the same mammary epithelial cells (MTB‐TANba429 mice), the miR‐200b/200a/429 cluster prevented Neu from inducing mammary epithelial hyperplasia and mammary tumor development. RNA sequencing revealed alterations in the extracellular matrix of the mammary gland and a decrease in stromal cells including myoepithelial cells in Neu transgenic mice. Immunohistochemistry for smooth muscle actin confirmed that mammary epithelial cells in control and MTB‐TANba429 mice were surrounded by a layer of myoepithelial cells and these myoepithelial cells were lost in MTB‐TAN mice with hyperplasia. Thus, we have shown for the first time that elevated expression of miR‐200 family members in mammary epithelial cells can completely prevent mammary tumor development in Neu transgenic mice possibly through regulating myoepithelial cells.
Year:
2025
Lung cancer, the leading cause of cancer mortality, exhibits diverse histologic subtypes and genetic complexities. Numerous preclinical mouse models have been developed to study lung cancer, but data from these models are disparate, siloed, and difficult to compare in a centralized fashion. In this study, we established the Lung Cancer Autochthonous Model Gene Expression Database (LCAMGDB), an extensive repository of 1,354 samples from 77 transcriptomic datasets covering 974 samples from genetically engineered mouse models (GEMM), 368 samples from carcinogen-induced models, and 12 samples from a spontaneous model. Meticulous curation and collaboration with data depositors produced a robust and comprehensive database, enhancing the fidelity of the genetic landscape it depicts. The LCAMGDB aligned 859 tumors from GEMMs with human lung cancer mutations, enabling comparative analysis and revealing a pressing need to broaden the diversity of genetic aberrations modeled in the GEMMs. To accompany this resource, a web application was developed that offers researchers intuitive tools for in-depth gene expression analysis. With standardized reprocessing of gene expression data, the LCAMGDB serves as a powerful platform for cross-study comparison and lays the groundwork for future research, aiming to bridge the gap between mouse models and human lung cancer for improved translational relevance. Significance: The Lung Cancer Autochthonous Model Gene Expression Database (LCAMGDB) provides a comprehensive and accessible resource for the research community to investigate lung cancer biology in mouse models.
Year:
2025
Women diagnosed with ovarian cancer frequently have a poor prognosis as their cancer is often diagnosed at more advanced stages when the cancer has metastasized. At this point surgery cannot remove all the tumor cells and while ovarian cancer cells often initially respond to chemotherapeutic agents like carboplatin and paclitaxel, resistance to these agents frequently occurs. Thus, novel therapies are required for the treatment of advanced stage ovarian cancer. One therapeutic option being explored is the regulation of non-coding RNAs such as microRNAs. An advantage of microRNAs is that they can regulate tens, hundreds and sometimes thousands of mRNAs in cells and thus may be more effective than chemotherapeutic agents or targeted therapies. To investigate the therapeutic potential of miR-200s in ovarian cancer, lentiviral vectors were used to overexpress both miR-200 clusters in two murine ovarian cancer cell lines, ID8 and 28–2. Overexpression of miR-200s reduced the expression of several mesenchymal genes and proteins, significantly inhibited proliferation as assessed by BrdU flow cytometry and significantly reduced invasion through Matrigel coated transwell inserts in both cell lines. Overexpression of miR-200s also increased basal apoptosis approximately 3-fold in both cell lines as determined by annexin V flow cytometry. Pathway analysis of RNA sequencing of control and miR-200 overexpressing ovarian cancer cells revealed that genes regulated by miR-200s were involved in processes like epithelial mesenchymal transition (EMT) and cell migration. Therefore, miR-200s can inhibit proliferation and increase apoptosis while suppressing tumor cell invasion and thus simultaneously target three key cancer pathways.
Year:
2024
Matrix-remodeling-associated protein 8 or MXRA8 is a transmembrane protein that can bind arthritogenic alpha viruses like the Chikungunya virus and provide viral entry into cells. MXRA8 can also interact with integrin β3 and thus possibly regulate cell–cell interactions and binding to the extracellular matrix. While MXRA8 has been associated with reduced survival in patients with colorectal and renal clear cell cancers, the role of MXRA8 in breast cancer remains largely unexplored. Therefore, the aim of this research was to determine the role of MXRA8 in breast cancer by knocking out MXRA8 in the human triple-negative breast cancer cell line MDA-MB-231. The loss of MXRA8 reduced cell proliferation in vitro but had no effect on apoptosis or migration in cultured cells. However, the loss of MXRA8 significantly delayed tumor development and reduced metastatic dissemination to the lungs in a xenograft model. RNA sequencing identified three genes, ADMATS1, TIE1, and BMP2, whose expression were significantly reduced in MXRA8-knockout tumors compared to control tumors. MXRA8 staining of a human breast cancer tissue array revealed higher levels of MXRA8 in primary tumors and metastases of aggressive tumor subtypes (TNBC and HER2+) compared to less aggressive, ER+ breast cancers. Our findings demonstrate for the first time that MXRA8 regulates the progression of human TNBC possibly through influencing the interaction of tumor cells with their microenvironment.
Year:
2023
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Collaborators (23)
Kekoa Taparra
Assistant Professor
University of California, Los Angeles
John Minna
Professor and Direcdtor
University of Texas Southwestern Medical Center
Vassilis Aidinis
Biomedical Sciences Research Center Alexander Fleming
Barbara Grüner
University Hospital Essen
Phuoc T. Tran
University of Maryland
Pawel Mazur
Associate Professor
The University of Texas MD Anderson Cancer Center
Ralph J. DeBerardinis
University of Texas Southwestern Medical Center
Charles Rudin
Memorial Sloan Kettering Cancer Center
J. Edward van Veen
Assistant Adjunct Professor
University of California, Los Angeles
George Acquaah-Mensah
Professor of Pharmaceutical Sciences
Massachusetts College of Pharmacy and Health Sciences
Yonathan Lissanu
The University of Texas MD Anderson Cancer Center
Trudy G. Oliver
Duke University
YING GAO
University of Texas Southwestern Medical Center
David MacPherson
Professor
Fred Hutch Cancer Center
Giorgio Ramadori
Scientific Collaborator
University of Geneva
Rosanna Martinelli
Professor of Molecular Biology
Università degli Studi di Napoli Federico II
Min Gyu Lee
Professor
The University of Texas MD Anderson Cancer Center
Shyam Biswal
Professor
Johns Hopkins University
Arun Pandiri
Staff Scientist
National Institute of Environmental Health Sciences
CHARLES POWELL
Division Chief/Professor of Medicine
Icahn School of Medicine at Mount Sinai
Jennifer Beane-Ebel
Assistant Professor
Boston University School of Medicine
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.